Control
Recent:Fakharian.
Dec 18 2021 |
et al., Immunopathologia Persa, doi:10.34172/ipp.2022.30322 | A randomized clinical trial study on the efficacy and safety of adalimumab and methylprednisolone pulse therapy in the treatment of COVID-19 patients with acute respiratory distress syndrome |
| RCT 80 ICU patients with moderate to severe COVID-19 showing reduced hospital stay with adalimumab plus methylprednisolone compared to methylprednisolone alone, however authors excluded patients that died without reporting how many died. .. | ||
Oct 31 2021 |
et al., International Immunopharmacology, doi:10.1016/j.intimp.2021.107961 | Evaluation of adalimumab effects in managing severe cases of COVID-19: A randomized controlled trial |
| no change in mortality (p=1), 33% higher ventilation (p=1), and no change in ICU admission (p=1). RCT 68 hospitalized patients with severe COVID-19 showing no significant differences with adalimumab treatment. | ||
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. IMA and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.